Navigation Links
iCo Therapeutics Closes $1.3 Million Private Placement
Date:2/9/2009

VANCOUVER, Feb. 9 /PRNewswire-FirstCall/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce the completion of a $1,292,500 non-brokered private placement. This financing provides the company with sufficient capital to develop iCo-007 through to the completion of the Phase 1 clinical trial. iCo-007 is targeting the treatment of Diabetic Macular Edema. The balance of funds will provide the company with additional working capital. iCo's partner Isis Pharmaceuticals Inc., (NASDAQ: ISIS), participated as a lead investor in the financing, along with select insiders and existing shareholders.

"We are pleased to be able to invest in the advancement of iCo-007, a promising drug in our pipeline being developed with the ocular disease expertise of our partners at iCo," said B. Lynne Parshall, COO and CFO of Isis Pharmaceuticals. "This funding will help move iCo-007 to a key value inflection point by supporting completion of the ongoing study in patients with diffuse macular edema. iCo-007 is a product of our satellite company strategy to exploit antisense technology beyond our core areas of focus to provide new treatment options in a broad range of diseases. With the benefit of our strong financial position, strengthening our pipeline in a variety of ways is a key strategic imperative. This transaction represents one step toward achieving that goal."

The private placement represents 6,462,500 common shares and 3,231,250 million warrants. Each warrant will entitle the holder, on exercise, to purchase one additional Common Share at a price of $0.30 at any time prior to the date 12 months following the closing date. The closing of the first tranche of this placement, in the amount of $582,750, was announced on January 30th, 2009.

A finder's fee of 7% will be payable to certain arm's length third parties with respect to a portion of the private pl
'/>"/>

SOURCE iCo Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
2. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
3. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
4. Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share
5. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
6. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
7. Omnitura Therapeutics Announces Private Placement Financing
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. Cell Therapeutics Receives Additional NASDAQ Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 ... released today including improvements to the enterprise replication ... connectors for Lucene, SOLR and Elasticsearch. This release ... this high performance triplestore – GraphDB™ was formerly ... in deploying the only mature enterprise resilient RDF ...
(Date:8/19/2014)... 2014 Shimadzu Scientific Instruments has ... and Nexera-i, adding to the company’s extensive line-up ... an intuitive operating environment, and full automation, the ... workflow for conventional to ultra-high-speed analysis. ... intelligent design so users can begin building the ...
(Date:8/19/2014)... , Aug. 19, 2014 A Geisinger ... been nominated for a Centers for Disease Control and ... a major public health concern. Joseph ... is one of a team of researchers nominated for ... C. Shepard Science Award for Data Methods and Study ...
(Date:8/19/2014)... Research and Markets  has announced the addition ... Strategic Business Report" report to their offering. ... Fuel Cells (SOFCs) in US$ Thousands. The report provides separate ... Europe , Asia-Pacific , ... for the period 2012 through 2020. Market data and analytics ...
Breaking Biology Technology:Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... Couples can choose child,s gender with less ethically charged ... Bay Area SAN RAMON, Calif., May 13 In ... choose the sex of their next child, the Reproductive ... announced today that it now is offering an alternative ...
... (OTC Bulletin Board: SCIE), a San Diego based ... established a distribution partnership for the German and ... specializing in the marketing and distribution of innovative ... and Marketing, commented, "We are pleased to add ...
... DIEGO, May 13 Dr. Feng Lin, Director of ... BMSN) and Entest BioMedical Inc., today stated that he ... injury" (TBI) using autologous "adipose-derived" stem cells represents a ... both Bio-Matrix and Entest BioMedical are now studying the ...
Cached Biology Technology:Gender-Selection Technique Embraced for Hopeful Parents 2SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria 2SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria 3'Adipose-derived' Stem Cells Could Help Traumatic Brain Injury Patients, Says Bio-Matrix Scientific Group's, Entest BioMedical Inc. Researcher 2
(Date:8/20/2014)... A new gene therapy developed by researchers at the ... to protect mice from a life-threatening heart condition caused ... therapeutic avenue," said Yi Lai, Ph.D., the leading author ... MU School of Medicine,s Department of Molecular Microbiology and ... hope this could lead to a treatment for people ...
(Date:8/20/2014)... POINT ROBERTS, Washington , August 20, 2014 ... Role in Addressing Security Concerns in the Payment Industry? ... source covering leading sectors including biometrics, issues commentary from analysts ... Jason Peaslee , Managing Partner at Thrive Analytics, ... Pereira , CEO of NXT-ID, Inc. (OTCBB: NXTD) ( OTCQB:NXTD ...
(Date:8/19/2014)... in supermarkets to encourage healthier spending habits? A new ... very question by tracking the purchasing records in a ... rate the nutritional value of foods for sale. , ... Just, PhD, and Brian Wansink PhD, author of Slim ... 150 Hannaford Supermarkets in the Northeastern United States between ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7
... COLUMBUS, Ohio Very few athletic trainers associated with ... were following best practice standards for managing asthma among ... athletes with asthma, the dangers of the condition can ... severe to be incapacitating, or deadly. The lead report ...
... and inanimate phenomena may have more in common than previously ... University engineer Adrian Bejan and Penn State biologist James Marden. ... theory that flow systems from animal locomotion to the ... and minimize imperfections. Flows evolve to reduce friction or other ...
... Conan Doyle,s account of an isolated community of dinosaurs that ... no less appeal now than it did when it was ... recreate the lost world of dinosaurs, but today the fiction ... suggests that dinosaur bones from the Ojo Alamo Sandstone in ...
Cached Biology News:Athletes with asthma need more help from their team trainers 2Unifying the animate and the inanimate designs of nature 2Evidence of the 'Lost World' -- did dinosaurs survive the end Cretaceous extinctions? 2
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... Maxi Kit provides a fast and simple procedure ... for buffer exchange, and for removing different types ... based on spin-column chromatography using Norgens patented protein ... MgCl 2 , NaCl, KCl, CaCl 2 , ...
... variant: With the macro- ... by Hoagland and Arnon ... Formulated to contain 1.6 ... per liter of medium. ...
Biology Products: